Drug
Pegylated interferon-alpha-2a
Pegylated interferon-alpha-2a is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_1
1
25%
Ph phase_4
1
25%
Ph phase_3
2
50%
Phase Distribution
1
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Other(1)
Detailed Status
Completed3
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (25.0%)
Phase 32 (50.0%)
Phase 41 (25.0%)
Trials by Status
completed375%
unknown125%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_1
Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy
NCT02471430
completedphase_3
Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB
NCT00204529
unknownphase_3
A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B
NCT01172392
completedphase_4
Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B
NCT00291616
Clinical Trials (4)
Showing 4 of 4 trials
NCT02471430Phase 1
Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy
NCT00204529Phase 3
Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB
NCT01172392Phase 3
A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B
NCT00291616Phase 4
Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4